Biogen
Forbes Global 2000 1978 #847 by revenue · BIIB United States Healthcare Drugs & Biotechnology biogen.com
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases.
Forbes Global 2000's description, shown to identify the company. We rate the name, not the business.
- Evocativity EVOC : green
- Bio and gen clearly evoke biotechnology
- Brevity BREV : green
- 6 letters, 2 syllables. Up to seven letters is green, eight at two syllables too; up to ten yellow, eleven or more red.
- Greppability GREP : red
- Found inside 23 other dictionary words.
- Googlability GOOG : yellow
- Established biological terminology offers minor competition
- Pronounceability PRON : green
- Bio-gen reads naturally
- Spellability SPEL : yellow
- Biogen versus Biogene is uncertain
- Verbability VERB : red
- Biological noun offers no natural action
- Nominology
- 75
- All seven dimensions and .com ownership, weighted as set out on Methodology.
- Fluency
- 100
- Brevity and pronounceability only: the subset with published outcome evidence behind it.
- PG grade
- 1 / 4
- Graham's own four-step ladder.
- Exact .com
- Owned
- Shape
- real word
- Length
- 6 chars, 2 syllables
- Distinctiveness
- suggestive
This row is stitched from more than one source. Forbes Global 2000 supplied the company; fortune500 filled ticker.
Rubric version 2026.10.20-1, judged by gpt-6.1-sol (agent).
This scores the name only. See Methodology.
These judged dimensions came from an AI agent working through the judging queue in a chat, on the same rubric the scoring pipeline sends. The agent passed the calibration exam before its work was accepted, and each batch it judged hid two names with known answers as a check. The model is named as the agent reported it.